The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer: An Open-label, Multi-center, Prospective and Randomised Study
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 438
- 试验地点
- 1
- 主要终点
- progression free survival
研究概览
简要总结
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
详细描述
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
XELOX
oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
干预措施: Oxaliplatin (Drug)
XELOX
oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
干预措施: Capecitabine (Drug)
EOX
Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
干预措施: Epirubicin (Drug)
EOX
Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
干预措施: Oxaliplatin (Drug)
EOX
Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
干预措施: Capecitabine (Drug)
结局指标
主要结局
progression free survival
时间窗: 7 months
次要结局
- overall survival(10 months)
- quality of life questionnaire(2 months)
- overall response rate(2 months)
- Number of Participants with Adverse Events(2 months)